Fatigue Prognostic for Survival in Certain Patients With Myelodysplastic Syndromes
the ONA take:
Self-reported fatigue severity provides prognostic information for survival independent from gold-standard risk classifications in patients with newly diagnosed higher-risk myelodysplastic syndromes, a new study published online ahead of print in the journal The Lancet Oncology has shown.
Because the clinical presentation of myelodysplastic syndromes can be highly variable, researchers sought to evaluate whether self-reported fatigue severity is prognostic for overall survival in higher-risk patients.
For the study, researchers enrolled 280 patients with myelodysplastic syndromes who were enrolled within 6 months of diagnosis with an intermediate-2-risk or high-risk score.
Results showed that the median overall survival from diagnosis was 17 months. Researchers found that high-risk International Prognostic Scoring System (IPSS) score and a higher score for fatigue were independently associated with reduced overall survival. Self-reported fatigue remained a statistically significant prognostic factor for survival in further multivariate analyses.
“Our findings suggest that fatigue assessment should be included in routine diagnostic investigation for these patients and considered as a standard baseline stratification factor in future randomized controlled trials,” the authors conclude.
Self-reported fatigue severity provides prognostic information for newly diagnosed higher-risk myelodysplastic syndromes.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|